Controlled Substances Act & Federal Drug Policy

The Controlled Substances Act (CSA, 1970) — codified at 21 U.S.C. Chapter 13 — is the federal law that classifies drugs into five schedules based on abuse potential and accepted medical use, and authorizes the DEA and DOJ to regulate their manufacture, distribution, and possession. Schedule I (heroin, LSD, MDMA, psilocybin, and — critically — marijuana) means the federal government classifies these as having high abuse potential and no currently accepted medical use, making them illegal under federal law regardless of state law. Schedule II covers high-risk drugs with accepted medical use (fentanyl, oxycodone, methamphetamine, cocaine), requiring prescriptions and strict DEA tracking. The most significant current tension: 38+ states have legalized marijuana for medical or recreational use, but marijuana remains Schedule I federally — creating a federal-state legal conflict that affects banking access, federal employment, and criminal penalties for conduct that is legal in the state where it occurs. The DEA, following an HHS recommendation (2023) and a Biden-administration NPRM on May 21, 2024 (89 FR 44597), has proposed but not yet finalized rescheduling marijuana to Schedule III — a move that would not legalize it federally but would reduce penalties and make federal research easier; the proposal remains pending under the Trump administration's DEA. The opioid epidemic has led the DEA to impose prescribing quotas on Schedule II opioids and require distributors to flag suspicious orders — a system whose adequacy was questioned in major litigation resulting in $26 billion+ in state settlements with distributors and manufacturers.

Current Law (2026)

Legal Authority

• 21 U.S.C. § 801 — Congressional findings (many drugs have useful medical purposes but also potential for abuse; illegal trafficking constitutes a threat to public health; federal control necessary because drug traffic is interstate and international)
• 21 U.S.C. § 802 — Definitions (controlled substance, schedule, narcotic drug, drug, manufacture, distribute, dispense, administer, practitioner, registration)
• 21 U.S.C. § 811 — Scheduling authority (Attorney General may add/remove/reschedule substances considering: actual/relative abuse potential, scientific evidence, pharmacological effect, history of abuse, risk to public health, psychic/physiological dependence liability, whether the substance is an immediate precursor; AG must request scientific evaluation from HHS; HHS medical/scientific findings are binding)
• 21 U.S.C. § 812 — Schedules of controlled substances (five schedules: I — high abuse potential, no accepted medical use, no accepted safety for use under medical supervision; II — high abuse potential but has accepted medical use; III-V — progressively lower abuse potential; initial placement of substances; examples)
• 21 U.S.C. § 821-829 — Registration and record-keeping (every person who manufactures, distributes, or dispenses controlled substances must register with DEA; quotas for Schedule I and II manufacturing; records and reports required; prescriptions: Schedule II requires written prescription, no refills; III-V allow phone prescriptions and refills)
• 21 U.S.C. § 841 — Prohibited acts (unlawful to manufacture, distribute, or dispense controlled substances except as authorized; unlawful to create, distribute, or possess with intent to manufacture; penalty structure tied to substance type and quantity)
• 21 U.S.C. § 844 — Simple possession (any person who knowingly possesses a controlled substance without a valid prescription is subject to imprisonment up to 1 year; repeat offenders face enhanced penalties)
• 21 U.S.C. § 846 — Attempt and conspiracy (any person who attempts or conspires to commit a drug trafficking offense is subject to the same penalties as the completed offense)
• 21 U.S.C. § 848 — Continuing Criminal Enterprise (CCE — the "drug kingpin" statute; mandatory 20-year minimum for organizing a continuing drug enterprise with 5+ people; life imprisonment for a principal leader)
• 21 U.S.C. § 860 — Enhanced penalties near schools (distribution within 1,000 feet of a school doubles the maximum punishment; mandatory 1-year minimum additional)

Implementing Regulations (21 CFR Parts 1300-1321)

• 21 CFR Part 1301 — Registration of manufacturers, distributors, and dispensers: DEA registration requirements for all handlers of controlled substances; separate registrations for each activity and location; renewal, modification, and revocation procedures

• 21 CFR Part 1304 — Records and reports: every registrant must maintain complete records of controlled substance transactions — receipts, disposals, inventories (biennial); DEA Form 222 for Schedule I-II transfers; electronic prescribing standards

• 21 CFR Part 1306 — Prescriptions: Schedule II prescriptions must be written (no phone-in except emergency with 7-day follow-up); Schedule III-V may be oral or written; refill limits (no refills for Schedule II; up to 5 refills in 6 months for III-V); electronic prescribing for controlled substances (EPCS)

• 21 CFR Part 1308 — Schedules of controlled substances: lists all substances by schedule (I-V); procedures for adding, removing, or rescheduling; temporary scheduling authority for imminent hazards (up to 2 years)

• 21 CFR Part 1311 — Electronic prescribing of controlled substances (EPCS): requirements for electronic prescription applications, identity proofing, two-factor authentication, audit trails

• 21 CFR Part 1314 — Retail Sale of Scheduled Listed Chemical Products: the implementing rules for the Combat Methamphetamine Epidemic Act of 2005 (CMEA), which brought retail pseudoephedrine (ephedrine, pseudoephedrine, and phenylpropanolamine) sales under federal control to reduce domestic meth manufacturing. These are the rules that require pharmacies and drug stores to keep cold medicine behind the counter and log purchaser IDs. Key provisions:

  • § 1314.20 — Daily and monthly purchase limits: a regulated seller may not sell any purchaser more than 3.6 grams per day of pseudoephedrine base (or ephedrine, or phenylpropanolamine base) regardless of the number of transactions; and not more than 9 grams per 30-day period per purchaser — the 30-day limit is tracked across all retailers through the electronic tracking systems (NPLEx — National Precursor Log Exchange — or equivalent); these limits translate to approximately 2–3 standard boxes of pseudoephedrine-based cold medicine per month
  • § 1314.25 — Behind-the-counter placement requirement: regulated sellers must place scheduled listed chemical products so that customers do not have direct access — products must be behind a counter or in a locked case; customers must request the product from a staff member before purchase; this is the origin of the familiar requirement that decongestant cold medicines be sold at the pharmacy counter rather than displayed on store shelves
  • § 1314.30 — Logbook and electronic tracking: except for a single package containing ≤60 mg of pseudoephedrine, the seller must maintain a written or electronic logbook of purchases, including: the product name, quantity sold, purchaser's name and address, date and time of sale, and the purchaser's government-issued photo ID; purchasers must sign the logbook; most large pharmacy chains have transitioned to electronic point-of-sale systems connected to NPLEx, which provides real-time tracking across participating states and flags potential over-limit purchases
  • § 1314.05 — Packaging requirements: non-liquid forms (tablets, gel caps) must be packaged in blister packs (with no more than 2 dosage units per blister) or in unit-dose packages; bulk packaging of pseudoephedrine tablets is prohibited for retail sale; this requirement reduces the ease of dissolving large quantities for meth production
  • § 1314.35 / § 1314.40 — Training and self-certification: regulated sellers must train their sales personnel on the purchase restrictions and logbook requirements; sellers must submit a self-certification to DEA (DEA Form for self-certification, fee $21) demonstrating compliance with training requirements; without self-certification, a seller may not sell scheduled listed chemical products
  • § 1314.10 — State law not preempted: Part 1314 establishes federal minimums; states may impose stricter requirements; some states have enacted tighter limits or have required prescriptions for pseudoephedrine (Oregon and Mississippi require prescriptions, effectively eliminating over-the-counter pseudoephedrine sales in those states); the federal limits do not prevent states from going further

  The CMEA's retail controls effectively ended the large domestic pseudoephedrine-to-meth "super lab" industry in the U.S. — home labs could no longer easily stockpile pseudoephedrine. However, the drug policy has had unintended consequences: meth production shifted to Mexico-based "P2P meth" using phenylacetone (not subject to CMEA), which actually produces a more potent and dangerous product; and pseudoephedrine-containing OTC medicines became significantly less accessible to legitimate cold and allergy sufferers who must now interact with pharmacy staff and show ID for every purchase. The logbook system generates useful law enforcement data but also created a practical inconvenience burden on the approximately 10+ million Americans who use pseudoephedrine medications annually for legitimate decongestant purposes.

• 21 CFR Part 1315 — Importation and production quotas for ephedrine, pseudoephedrine, and phenylpropanolamine: the annual quota system that caps total U.S. production and importation of meth precursor chemicals. Key provisions:

  • § 1315.06 — Four types of quotas: (1) Assessment of Annual Needs — the DEA-fixed aggregate cap on total U.S. production/importation; (2) Individual Manufacturing Quota — each registrant's allocation from the aggregate cap; (3) Procurement Quota — amount a registrant may purchase for further processing; (4) Import Quota — capped authorization for importation of bulk active pharmaceutical ingredients
  • § 1315.11 — Assessment of Annual Needs: the Administrator determines total national need based on legitimate medical, scientific, research, and industrial uses, adjusted for diversion into illicit manufacture. DEA publishes the aggregate assessment each year, and no manufacturer may produce more than its allocated share of the aggregate.
  • § 1315.21–1315.23 — Individual manufacturing quotas: each manufacturer registered to produce bulk ephedrine, pseudoephedrine, or phenylpropanolamine must apply annually by July 1 on DEA Form 189. The DEA allocates based on each applicant's prior year net disposal, estimated needs, and stock in hand — manufacturers who did not need their full prior quota receive reduced future allocations. An inventory allowance of up to 60 days' supply is built into each quota.
  • § 1315.25 — Mid-year increases: a registrant who needs more than its quota (due to increased legitimate demand) may apply for an increase; DEA may approve if the aggregate has not been reached and the additional quota would not contribute to diversion.
  • §§ 1315.31–1315.36 — Procurement quotas: manufacturers of finished dosage forms who buy bulk pseudoephedrine for pressing into tablets must hold a procurement quota — a separate authorization from the manufacturing quota that covers the purchase, not the production. This dual-quota structure means diverters cannot simply acquire chemical by buying from multiple registered manufacturers; each purchase requires its own quota authorization.

• 21 CFR Part 1309 — Registration of Manufacturers, Distributors, Importers and Exporters of List I Chemicals (34 sections — the DEA's registration framework for the chemical precursors most commonly used in illicit drug manufacturing; List I chemicals include ephedrine, pseudoephedrine, phenylpropanolamine, norpseudoephedrine, and a growing list of fentanyl precursors as the DEA updates designations under 21 U.S.C. § 802(34)):

  • § 1309.21 — Persons required to register: any person who manufactures, distributes, imports, or exports a List I chemical must register with the DEA; registration is per activity and per location — a company that both manufacturers and distributes must hold separate registrations for each activity; a company with two manufacturing sites must register each site separately; there are no exemptions for companies below a threshold size — even small-batch manufacturers of pseudoephedrine or ephedrine must register
  • § 1309.22 — Separate registration for independent activities: the following activities each require separate registration: manufacturing for distribution, manufacturing for internal use, distributing, importing, and exporting; a company that imports and then distributes must hold both an import registration and a distribution registration; this prevents a single registration from authorizing multiple activities without oversight of each
  • § 1309.24 — Waivers: certain activities are exempt from registration, including law enforcement officers acting in their official capacity, common carriers transporting List I chemicals, and retailers who purchase regulated products for sale to consumers (retail sale is governed by Part 1314 purchase limits, not Part 1309 manufacturer/distributor registration)
  • § 1309.31 — Expiration: all List I chemical registrations expire on April 30 of each year and must be renewed annually; annual renewal requires submission of DEA Form 510 with documentation of legal business activity, no adverse legal actions, and compliance with the quota system
  • § 1309.11 — Registration fees: fees for List I chemical registration are set by DEA regulation; for 2026, fees range from $837 for retail distributors to $6,021 for manufacturers; fees fund DEA's Diversion Control Program which enforces both Part 1309 and the controlled substance registration framework under Part 1301
  • § 1309.72 — Suspicious orders: registered distributors of List I chemicals must design and maintain a system to identify suspicious orders — orders of unusual size, orders deviating substantially from normal buying patterns, or orders of unusual frequency; suspicious orders must be reported to the DEA before they are shipped; this requirement parallels the suspicious order monitoring obligations for controlled substance distributors under Part 1301; the opioid crisis enforcement against distributors who ignored suspicious opioid orders has heightened compliance focus on this provision across the entire registrant base

  List I chemical regulation (Part 1309) operates as a supply chain chokepoint targeting the chemical inputs for methamphetamine, as the quota system (Part 1315) is the cap on how much can be produced. In 2023-2024, the DEA added several fentanyl precursor chemicals to the List I schedule — including 4-ANPP (4-anilinopiperidine) and NPP (N-phenethyl-4-piperidone) — recognizing that illicit fentanyl manufacturing increasingly uses chemical routes rather than direct importation of finished drug. This expansion of List I means that chemical companies supplying these substances to pharmaceutical and industrial customers now require DEA registration and are subject to suspicious order reporting. Recent rulemakings: 81 FR 97021 (December 2016) — updated fee structure; 60 FR 32454 (June 1995) — original registration framework.

The pseudoephedrine quota system is one of the few U.S. examples of a production cap on a legal pharmaceutical ingredient — more typical of Schedule I and II controlled substances. The system was tightened by the Combat Methamphetamine Epidemic Act of 2005 (which added retail purchase limits and logbook requirements at pharmacies under Part 1314) and by ongoing DEA adjustments that reduced aggregate production quotas as illicit methamphetamine switched from pseudoephedrine-based production to precursor chemicals imported from Mexico. The domestic quota cap effectively ended large-scale domestic pseudoephedrine-to-meth "super labs" — the remaining meth supply is now predominantly produced from phenylacetone (P2P) and other non-quota chemicals.

• 21 CFR Part 290 — Controlled Drugs (FDA Labeling and Dispensing Requirements): while the DEA regulations (Parts 1301–1321 above) govern the supply chain and registration of controlled substance handlers, Part 290 is FDA's corresponding rule setting labeling and dispensing standards for controlled substances at the point of patient care:

  • § 290.1 — Prescription requirement: any drug listed in Schedule II, III, IV, or V of the Controlled Substances Act must be dispensed by prescription only as required by 21 U.S.C. § 503(b)(1); the prescription requirement is a joint mandate of both FDA and DEA — FDA enforces labeling compliance, DEA enforces diversion controls
  • § 290.5 — Required warning label: the label of any Schedule II, III, or IV controlled substance dispensed to a patient must contain the statement: "Caution: Federal law prohibits the transfer of this drug to any person other than the patient for whom it was prescribed." This warning must appear on the dispensing label attached to the container — it is the familiar cautionary statement on controlled substance prescription bottles that millions of Americans see on their prescription labels. The warning is not required on drugs dispensed for use in clinical investigations (where a different patient information framework applies)
  • § 290.6 — Spanish-language version: Section 305(c) of the Controlled Substances Act requires that the § 290.5 warning also be available in Spanish: "Precaucion: La ley Federal prohíbe la transferencia de esta droga a cualquier persona que no sea el paciente para quien fue prescrita." Pharmacies serving Spanish-speaking populations should use the Spanish warning when dispensing to patients who use Spanish as their primary language
  • § 290.2 — Schedule V codeine exemption: the prescription-dispensing requirement does not apply to compound preparations containing not more than 200 mg of codeine per 100 mL or 100 g that also contain at least one other active nonnarcotic medicinal ingredient in sufficient proportion to confer value beyond the codeine component; this is the regulatory basis for OTC codeine cough syrups (where state law permits), which are Schedule V products sold without a prescription in states that allow it — though most states now require prescriptions for codeine even in these concentrations
  • § 290.10 — Emergency oral prescription for Schedule II: a prescriber may authorize an emergency Schedule II prescription orally if: (a) immediate administration is necessary for proper treatment; (b) no appropriate alternative is available; and (c) it is not reasonably possible to obtain a written prescription prior to dispensing; the prescriber must then furnish a written prescription to the pharmacist within 7 days; the dispensing pharmacist must annotate the phone-in prescription with the prescriber's name and the word "emergency"

  Part 290 represents FDA's end of the dual-agency controlled substance framework — DEA controls who can handle these drugs and in what quantities; FDA ensures that patients who receive them are properly warned about the legal restriction on sharing or transferring prescription medications. The "Federal law prohibits transfer" warning, first required in the 1960s, predates the modern controlled substance scheduling system and remains one of the most-read mandatory label statements in U.S. pharmaceutical regulation. No major rulemakings since the original rule. The Schedule V codeine exemption has become less practically significant as states have increasingly required prescriptions for all codeine-containing products regardless of concentration.

• 28 CFR Part 76 — Rules of Procedure for Assessment of Civil Penalties for Possession of Certain Controlled Substances (42 sections — the DOJ's administrative adjudication framework implementing 21 U.S.C. § 844a, the civil penalty alternative for first-time simple possession of controlled substances enacted by the Anti-Drug Abuse Act of 1988; authority: 21 U.S.C. § 844a; 28 U.S.C. § 509). § 844a created a discretionary civil penalty track for first-time, personal-use possession offenses — the government may pursue either criminal prosecution under § 844 or a civil penalty proceeding, but not both, and may not proceed civilly if the person was previously convicted of a drug offense. Civil penalties under § 844a are capped at $10,000 and require the person to be referred to a drug assessment and possible treatment program. Part 76 establishes the administrative procedural framework for these proceedings before DOJ Administrative Law Judges (ALJs). Key provisions:

  • § 76.1 — Purpose: establishes the rules governing civil penalty proceedings against persons who knowingly possess a controlled substance for personal use under § 844a; the rules apply whenever the United States elects the civil penalty route rather than criminal prosecution
  • § 76.6 — Service of complaint: the DOJ serves the respondent with a written complaint specifying the substance possessed, the amount, date, and place, and the proposed civil penalty amount; respondent has 45 days to file a written answer; failure to answer is treated as an admission of the allegations
  • § 76.11–76.16 — Hearing procedures: ALJ conducts a formal hearing; parties are the United States and the respondent; the separation-of-functions requirement (§ 76.14) bars investigative or prosecutive DOJ staff from participating in the decision; ex parte communications with the ALJ are prohibited (§ 76.15)
  • § 76.19 — Burden of proof: the government bears the burden of proving, by a preponderance of the evidence, that the respondent knowingly possessed a controlled substance for personal use; the respondent may contest the amount of the proposed penalty
  • § 76.22 — Factors in penalty assessment: the ALJ considers the following when fixing the penalty amount within the $10,000 cap: (a) prior criminal drug convictions; (b) the circumstances of the possession; (c) the person's ability to pay; and (d) the deterrent effect of the penalty; the ALJ may also reduce a penalty or dismiss the case if the respondent completes a drug assessment and any required treatment
  • § 76.30 — Final order and judicial review: the ALJ's initial decision becomes final unless the respondent petitions for review to the Administrator; the final civil penalty is a debt owed to the United States and may be collected by civil action in federal district court; the respondent has a right to judicial review in the court of appeals

  The § 844a civil penalty track has been used sparingly — DOJ typically prefers criminal prosecution for possession offenses and the $10,000 cap limits its deterrent value for anything beyond first-time, small-quantity personal use. However, the program represents the federal government's sole administrative (non-criminal) enforcement mechanism for simple drug possession and is the regulatory basis for civil penalty referrals in lieu of prosecution in appropriate cases.

How It Works

The Controlled Substances Act is the foundation of federal drug policy — creating a comprehensive regulatory system that controls the manufacture, distribution, and possession of psychoactive substances through a scheduling framework, registration system, and criminal penalties.

The CSA classifies every controlled substance into one of five schedules based on medical utility, abuse potential, and safety. Schedule I (highest restriction) covers substances with high abuse potential and no currently accepted medical use — heroin, LSD, marijuana (at the federal level), MDMA, psilocybin — which can only be used in DEA-authorized research and cannot be prescribed. Schedule II covers high abuse potential but accepted medical use — fentanyl, oxycodone, hydrocodone, cocaine, methamphetamine, Adderall — requiring written prescriptions, no refills, and strict quantity limits. Schedules III-V cover progressively lower abuse potential, including testosterone (III), benzodiazepines (IV), and codeine-containing cough preparations (V). Scheduling determines everything: prescribing rules, manufacturing quotas, record-keeping, trafficking penalties, and the legal status of possession. The CSA also requires everyone who handles controlled substances to register with the DEA — approximately 1.8 million registrants including physicians, pharmacists, hospitals, manufacturers, distributors, and researchers — with obligations for transaction records, theft reporting, security compliance, and prescribing rules. DEA can revoke registration for violations, effectively ending a practitioner's ability to prescribe.

Criminal penalties under the CSA are tied to substance type and quantity, with mandatory minimums governing trafficking (manufacture and distribution). Key thresholds under 21 U.S.C. § 841: 5 kg+ cocaine, 1 kg+ heroin, or 100 grams+ of fentanyl trigger a 10-year mandatory minimum to life imprisonment; 500 grams+ cocaine, 100 grams+ heroin, or 40 grams+ fentanyl trigger a 5-year minimum to 40 years. Prior felony drug convictions double the mandatory minimums. The Fair Sentencing Act (2010) reduced the crack/powder cocaine sentencing disparity from 100:1 to 18:1, and the First Step Act (2018) made this retroactive while expanding the "safety valve" — allowing judges to sentence below mandatory minimums for qualifying non-violent, non-leadership offenders.

Marijuana remains a Schedule I substance under federal law — the same category as heroin — despite 24 states plus D.C. having legalized recreational use and 38+ states permitting medical marijuana as of 2026. This federal-state conflict means conduct legal under state law remains a federal crime; the DOJ has generally followed a non-enforcement approach for state-licensed operations while Congress has annually prohibited DOJ from spending funds to interfere with state medical marijuana programs (Rohrabacher-Blumenauer amendment). DEA published a notice of proposed rulemaking on May 21, 2024 (89 FR 44597) to move marijuana to Schedule III — which would recognize medical use, reduce federal research barriers, and lift the Section 280E tax burden blocking cannabis businesses from deducting ordinary business expenses — but the rule has not been finalized and marijuana remains Schedule I federally as of early 2026. The opioid crisis runs parallel: fentanyl — a synthetic opioid 50-100x more potent than morphine, primarily manufactured by Mexican cartels using Chinese precursors — drives approximately 75,000 overdose deaths per year, the deadliest drug crisis in American history. Federal enforcement has focused on border interdiction, international cooperation, and targeting distribution networks, while Congress has debated permanent class-wide scheduling of fentanyl analogs.

How It Affects You

If you're prescribed Schedule II or III controlled substances: The rules vary by schedule, and knowing the difference prevents surprises at the pharmacy.

Schedule II (Adderall, Ritalin, oxycodone, hydrocodone, fentanyl patches, methadone): requires a written or electronic prescription — no phone-in orders (except genuine emergencies, with a follow-up written prescription within 7 days). No refills — you need a new prescription each time. Most states impose additional limits: 30-day supplies, mandatory prescription drug monitoring program (PDMP) checks before dispensing, and early fill limits (typically no sooner than 75% through your current supply). Electronic prescribing (EPCS) is now mandatory in many states (New York, Minnesota, Texas, Connecticut, and others) and required for Medicare prescriptions federally.

Schedule III-V (most benzodiazepines are Schedule IV, tramadol is Schedule IV, some cough syrups are Schedule V): your prescriber can call these in, and you can get up to 5 refills within 6 months. Still subject to PDMP monitoring.

Telemedicine and controlled substances: The DEA's Ryan Haight Act generally requires an in-person medical evaluation before a practitioner can prescribe Schedule II-V controlled substances via telemedicine. COVID-era exceptions allowing remote prescribing for established patients were extended through 2025; the DEA issued final rules in 2024 permitting ongoing telemedicine prescribing for buprenorphine (addiction treatment) and some other substances with registration in a new special registry. If you receive controlled substances via telehealth, verify your prescriber's DEA registration before your prescription lapses.

If you lose or have a Schedule II prescription stolen: Contact your prescriber immediately — they will generally need to verify with the pharmacy and PDMP before issuing a replacement. A police report helps document the loss. Pharmacies can verify DEA database records. Some states prohibit replacing Schedule II prescriptions at all within a 30-day period; your prescriber knows your state's rules.

If you live or work in a state that has legalized marijuana: State legalization does not protect you from federal consequences — and those consequences are real, not hypothetical:

• Federal employment: All federal agencies test for marijuana (Schedule I). More critically: DOD, intelligence community, FBI, DEA, ATF, and Secret Service may impose lifetime or 10-year bars on applicants who have used marijuana, regardless of state law. Even for agencies with shorter lookback windows, recent or heavy use will disqualify you.
• Security clearances: The 2019 National Security Adjudicative Guidelines list "illegal drug use" as a disqualifying condition — marijuana use counts, even in legal states, because federal clearances apply federal law. Each case is adjudicated individually, and older use with documented cessation is often mitigated. Recent use rarely is.
• Federally subsidized housing: HUD's Section 8 (Housing Choice Voucher) program mandates drug-free conditions. Marijuana use can result in eviction or termination of housing assistance even in states where it's legal. Local public housing authorities set and enforce their own marijuana policies within this federal framework.
• Firearms: Under 18 U.S.C. § 922(g)(3), it is illegal for an "unlawful user of a controlled substance" to possess firearms or ammunition. ATF Form 4473 (required for every commercial gun purchase) asks specifically whether you're an unlawful user of controlled substances — answering dishonestly is a federal felony. The Ninth Circuit (United States v. Daniels, 2023) upheld the marijuana/firearms prohibition. Practically: if you're a regular marijuana user in a legal state, you cannot legally purchase or possess a firearm under federal law.
• Immigration: Any marijuana use — even lawful under state law — can make a noncitizen inadmissible, deportable, or ineligible for naturalization. The "good moral character" requirement is violated by controlled substance use. USCIS has held this even where the applicant used marijuana legally under state law.
• Interstate transport: Carrying marijuana across state lines — even between two legal states — is a federal crime under 21 U.S.C. § 841. Airport security (TSA) operates under federal authority; marijuana discovered at TSA checkpoints is referred to local law enforcement, but the federal transport prohibition remains.
• Federal property: National parks, military bases, federal buildings — no marijuana, even in legal states.

Rescheduling update: The DEA published a notice of proposed rulemaking on May 21, 2024 (89 FR 44597) to move marijuana from Schedule I to Schedule III (following an HHS scientific/medical recommendation). DEA hearings were held but the rule has NOT been finalized as of early 2026 — marijuana remains Schedule I federally, and Section 280E continues to bar state-licensed cannabis companies from deducting ordinary business expenses. The proposal remains pending under the Trump administration's DEA.

If you're struggling with opioid addiction or know someone who is: Federal law now makes two critical medications easier to access than ever before.

Buprenorphine (Suboxone, Subutex): The DEA's X-waiver requirement was eliminated by Congress in December 2022 (Consolidated Appropriations Act, 2023). Any DEA-registered healthcare provider — your primary care doctor, your psychiatrist, a urgent care clinic — can now prescribe buprenorphine for opioid use disorder (OUD), with no special training or patient limits required. If your provider is reluctant, find one at findtreatment.gov or call SAMHSA's free, confidential, 24/7 helpline: 1-800-662-HELP (4357).

Methadone: Still requires treatment through a licensed Opioid Treatment Program (OTP). SAMHSA's opioid treatment program locator: findtreatment.gov. COVID-era take-home flexibilities (allowing more doses without in-person visits) have been extended into permanent rule.

Naloxone (Narcan): The FDA approved OTC naloxone in 2023 — no prescription required. Available at Walgreens, CVS, Rite Aid, and most major pharmacies. If you or someone you know uses opioids, keep naloxone on hand. In 47+ states, Good Samaritan laws protect people who call 911 for an overdose from drug possession prosecution. Using naloxone is not an admission of drug use.

If you're charged with a federal drug offense or consulting someone who is: Mandatory minimums are the defining feature of federal drug sentencing — but several exceptions exist.

Key trafficking thresholds (21 U.S.C. § 841):

• 10-year minimum to life: 5+ kg cocaine, 1+ kg heroin, 280+ g crack, 40+ g pure fentanyl, 100+ g meth (pure)
• 5-year minimum to 40 years: 500+ g cocaine, 100+ g heroin, 28+ g crack, 10+ g pure fentanyl, 5+ g meth (pure)
• Prior drug felony conviction can double the mandatory minimum — this is why prior record review is critical immediately.

The safety valve (18 U.S.C. § 3553(f), expanded by the First Step Act of 2018): If you have (1) not more than 4 criminal history points, (2) no prior 3-point offense, (3) no prior 2-point violent offense, (4) no violence/threats/weapons in the offense, (5) you were not an organizer or leader, and (6) you truthfully provide all information to the government — a judge may sentence below the mandatory minimum. Meeting all six criteria requires detailed pre-sentencing preparation with counsel.

Cooperation (18 U.S.C. § 3553(e)): The government may file a motion for a sentence below the mandatory minimum based on "substantial assistance" — information about other people's crimes. Distinct from the safety valve; requires government agreement.

First Step Act credits: Eligible federal drug offenders can earn 10-15 days of time credits per 30 days of participation in approved programming, applied toward early supervised release. Minimum and low security inmates earn 15 days/month. These credits can meaningfully shorten time served.

For resources: FAMM (Families Against Mandatory Minimums, famm.org) tracks federal drug sentencing and can connect defendants' families with advocacy and information. Federal defender offices (in each federal judicial district) provide representation for those who cannot afford counsel.

State Variations

Drug scheduling and enforcement vary enormously by state:

• Marijuana legalization: 24 states + DC have legalized recreational use; 38+ have medical programs; federal Schedule I classification remains unchanged
• Most states have their own controlled substance schedules that generally mirror federal schedules but may differ (some states have scheduled substances not federally scheduled, and vice versa)
• State drug penalties range from decriminalization (Oregon, 2020 — later partially reversed) to severe mandatory minimums
• Prescription drug monitoring programs (PDMPs) are operated by states; all 50 states now have them
• Some states have enacted naloxone standing orders and Good Samaritan laws protecting those who call 911 for overdoses

Pending Legislation

• S 3618 / HR 6259 — No Fentanyl on Social Media Act. Requires social media platforms to remove content advertising or facilitating the sale of fentanyl and other controlled substances. Status: Introduced.
• S 3330 — Strengthening Sanctions on Fentanyl Traffickers Act. Expands sanctions authority targeting international fentanyl trafficking networks and precursor chemical suppliers. Status: Introduced.
• HR 7552 — CBW Fentanyl Act. Imposes sanctions on foreign persons and entities involved in chemical and biological weapons programs linked to fentanyl production. Status: Introduced.
• S 4209 — Extends the statute of limitations for controlled substance offenses that cause death. Status: Introduced.
• S 3334 — Prohibits reductions in the DEA workforce during the fentanyl crisis. Status: Introduced.
• HR 5744 — Targeting Online Sales of Fentanyl Act. Strengthens enforcement tools against online marketplaces used to traffic fentanyl and precursor chemicals. Status: Introduced.

Recent Developments

• DEA proposed rescheduling marijuana from Schedule I to Schedule III (NPRM published May 21, 2024, 89 FR 44597) — the most significant potential change in federal marijuana policy since 1970; the rule has not been finalized as of early 2026 and marijuana remains Schedule I, with Section 280E still applying to cannabis businesses
• The fentanyl crisis continues to drive enforcement and legislative action, with debate over class-wide scheduling of fentanyl analogs
• The elimination of the X-waiver (2023) removed barriers to buprenorphine prescribing, potentially expanding access to opioid addiction treatment
• Oregon's drug decriminalization experiment (Measure 110, 2020) has been partially rolled back after concerns about implementation and public drug use
• In March 2026, the DEA designated propionyl chloride as a List I chemical under the Controlled Substances Act, reflecting its use in the illicit manufacture of fentanyl and fentanyl analogs — part of the ongoing federal effort to disrupt precursor chemical supply chains fueling the fentanyl crisis.
• In March 2026, the DEA finalized placement of five designer benzodiazepines — clonazolam, diclazepam, etizolam, flualprazolam, and flubromazolam — in Schedule I of the Controlled Substances Act, finding these substances have high potential for abuse and no currently accepted medical use.
• MDMA-assisted psychotherapy: in August 2024, FDA issued a Complete Response Letter to Lykos Therapeutics declining to approve MDMA-assisted therapy for PTSD, citing concerns about trial blinding, durability of treatment effects, and adverse-event reporting; the FDA requested an additional Phase 3 trial. As of 2026, MDMA remains Schedule I and Lykos is preparing a resubmission